CAPR Faces Lawsuit and FDA Delay: Investor Alert
Trouble Brewin' for Capricor Investors Buckle up, folks. Capricor Therapeutics (NASDAQ: CAPR) is caught in a storm, facing not just the lengthy arm of law with a securities class action, but also a seemingly endless wait with the FDA's decision on their lead product. We're talking serious implications for anyone with skin in the game. The FDA's Delayed Blessing So the...
Continue Reading